KINECT-HD2

Kinect-HD2 is active, but not recruitingOpen-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated with Huntington’s Disease

Find this study on clinicaltrials.gov and the Huntington’s Study Group website.

SponsorHuntington Study Group & Neurocrine Biosciences, Inc.
The StudyAn open-label extension of the phase 3 KINECT-HD trial, which evaluated valbenazine (INGREZZA) for managing chorea, a hallmark symptom of Huntington's disease (HD). Valbenazine, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, was FDA-approved for treating HD chorea in 2023 based on results from these trials.

This extension study aims to confirm the long-term safety and effectiveness of valbenazine, including its use alongside antipsychotic medications, which are commonly prescribed to address neuropsychiatric symptoms in HD patients. Participants self-administer a once-daily dose of valbenazine, ranging from 20 mg to 80 mg, over a treatment period of up to 104 weeks. The study's design accommodates dose adjustments to suit individual needs while maintaining rigorous monitoring to assess outcomes and side effects.
PhaseIII